Shuang-Yin Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shuang-Yin Han has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Albert J. Wong
Department of Neurosurgery, Stanford University School of Medicine, 300 Pasteur Drive, Edwards Building Room 213, Stanford, CA 94305, USA
1 shared publication - Gordon Li
Department of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA
1 shared publication - Marina Holgado-Madruga
Brain Tumor Research Laboratories, Department of Neurosurgery, and Program in Cancer Biology, Stanford University Medical Center, Stanford, CA94305, USA
1 shared publication - Puja Gupta
Department of Neurosurgery, Brain Tumor Research Laboratories, Stanford University Medical Center, Stanford, CA 94305, USA
1 shared publication - Ryan Takeo Nitta
Department of Neurosurgery, Stanford University School of Medicine, Stanford, California
1 shared publication - Siddhartha S. Mitra
Department of Pediatrics, Center for Childhood Cancer and Blood Disorders, Division of Heme/Onc and Bone Marrow Transplant, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA
1 shared publication
Latest Publications
- Open Access
- 7 October 2010
- Published by Springer Nature in BMC Biotechnology
- Vol. 10 (1) , 72
Development of an EGFRvIII specific recombinant antibody
EGF receptor variant III (EGFRvIII) is the most common variant of the EGF receptor observed in human tumors. It results from the in frame deletion of exons 2-7 and the generation of a novel glycine residue at the junction of exons 1 and 8. This novel juxtaposition of amino acids within the extra-cellular domain of the EGF receptor creates a tumor specific and immunogenic epitope. EGFRvIII expression has been seen in many tumor types including glioblastoma multiforme (GBM), breast adenocarcinoma, non-small cell lung carcinoma, ovarian adenocarcinoma and prostate cancer, but has been rarely observed in normal tissue. Because this variant is tumor specific and highly immunogenic, it can be used for both a diagnostic marker as well as a target for immunotherapy. Unfortunately many of the monoclonal and polyclonal antibodies directed against EGFRvIII have cross reactivity to wild type EGFR or other non-specific proteins. Furthermore, a monoclonal antibody to EGFRvIII is not readily available to the scientific community.
- 7 October 2010
- Published by Springer Nature in BMC Biotechnology
- Vol. 10 (1) , 72
Open AccessDevelopment of an EGFRvIII specific recombinant antibody
EGF receptor variant III (EGFRvIII) is the most common variant of the EGF receptor observed in human tumors. It results from the in frame deletion of exons 2-7 and the generation of a novel glycine residue at the junction of exons 1 and 8. This novel juxtaposition of amino acids within the extra-cellular domain of the EGF receptor creates a tumor specific and immunogenic epitope. EGFRvIII expression has been seen in many tumor types including glioblastoma multiforme (GBM), breast adenocarcinoma, non-small cell lung carcinoma, ovarian adenocarcinoma and prostate cancer, but has been rarely observed in normal tissue. Because this variant is tumor specific and highly immunogenic, it can be used for both a diagnostic marker as well as a target for immunotherapy. Unfortunately many of the monoclonal and polyclonal antibodies directed against EGFRvIII have cross reactivity to wild type EGFR or other non-specific proteins. Furthermore, a monoclonal antibody to EGFRvIII is not readily available to the scientific community.